- VRTX +0.23%
Insider Sale at Vertex Pharmaceuticals Inc (VRTX): Director Sangeeta Bhatia Sells Shares
Yahoo Finance · 3 hours ago
Moderna
Search results
Students. Find a Vertex clinical trial. Volunteers who participate in clinical trials. help make new medicines a reality. Learn more. Featured Stories. View All Stories. Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.
- 401.08Add to watchlist+0.92 (+0.23%)At close:4:00 PM EDTFri. May 3, 2024401.10 +0.02 (+0.00%)After hrs:7:44 PM EDTFri. May 3, 2024Nasdaq Real Time Price (USD) · Market closed
- Open401.50High405.67Low397.59
- Mkt Cap103.66BP/E (TTM)28.90Div & YieldN/A & N/A
- Prev. Close400.1652 Wk. Low320.0152 Wk. High448.40
What analysts are sayingTop storiesRelated stocks
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases.
In 2023, we ranked #12 in the Mega Employer category. Vertex Pharmaceuticals strikes at the core of serious diseases to change people's lives – learn about our mission, values and recognition.
Dec 8, 2023 · BOSTON & ZUG, Switzerland -- (BUSINESS WIRE)--Dec. 8, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy, for the treatment of ...
Jan 30, 2024 · BOSTON -- (BUSINESS WIRE)--Jan. 30, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain.
Mar 21, 2024 · BOSTON -- (BUSINESS WIRE)--Mar. 21, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant po...
